title: Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay.
abstract: In vitro "high post-treatment platelet reactivity" (HPPR) measured with light transmittance aggregometry (LTA) and the VerifyNow P2Y(12) assay has been associated with an increased risk of ischemic events after percutaneous coronary intervention (PCI). However, there are many criteria for HPPR according to the methods used for assessment, and correlations among suggested criteria have not been evaluated. To this end, we enrolled 1,058 unselected patients undergoing PCI in real clinical practice, simultaneously assessed platelet measures with LTA (both 5 and 20 μmol/l ADP-induced) and the VerifyNow P2Y(12) assay, and based on previous studies, evaluated the following criteria for HPPR: 5 or 20 μmol/l ADP-induced maximal platelet reactivity (PR(max)) ≥50%; 5 μmol/l ADP-induced late PR (PR(late)) >14%; 20 μmol/l ADP-induced PR(max) ≥62%; and P2Y(12) reaction unit (PRU) ≥240. Receiver-operating characteristics (ROC) curve analysis demonstrated that PRU (cut-off = 241) distinguished between patients with and without 5 μmol/l ADP-induced PR(max) ≥50% (area under curve [AUC] 0.822, sensitivity 83.0%, specificity 66.0%, P < 0.001), and 20 μmol/l ADP-induced PR(max) ≥62% (AUC 0.840, sensitivity 80.7%, specificity 71.4%, P < 0.001), respectively. PRU ≥240 showed a moderate agreement with 5 μmol/l ADP-induced PR(max) ≥50% (κ = 0.438, concordant rate 71.6%, P < 0.001) and 20 μmol/l ADP-induced PR(max) ≥62% (κ = 0.505, concordant rate 75.1%, P < 0.001). Cut-offs matched for 20 μmol/l ADP-induced PR(max) ≥50% (PRU = 195) and 5 μmol/l ADP-induced PR(late) >14 (PRU = 194) also were similar. The presence of significant correlations between the suggested criteria for HPPR has practical implications on the possible use of the VerifyNow P2Y(12) assay for risk stratification in PCI-treated patients.
authors.affiliation: Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea.
authors.forename: In-Suk
authors.initials: IS
authors.lastname: Kim
authors.forename: Young-Hoon
authors.initials: YH
authors.lastname: Jeong
authors.forename: Min-Kyung
authors.initials: MK
authors.lastname: Kang
authors.forename: Jin-Sin
authors.initials: JS
authors.lastname: Koh
authors.forename: Yongwhi
authors.initials: Y
authors.lastname: Park
authors.forename: Seok-Jae
authors.initials: SJ
authors.lastname: Hwang
authors.forename: Choong Hwan
authors.initials: CH
authors.lastname: Kwak
authors.forename: Jin-Yong
authors.initials: JY
authors.lastname: Hwang
authors.forename: Sunjoo
authors.initials: S
authors.lastname: Kim
mesh_terms: D000368:Aged; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008027:Light; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000097:blood*; D010979:Platelet Function Tests / Q000379:methods; D058925:Receptors, Purinergic P2Y12 / Q000097:blood*; D016896:Treatment Outcome
chemical_list: C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12
references.citation: J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16
references.pmid: 17418288
references.citation: Thromb Res. 2007;119(3):277-84
references.pmid: 16563469
references.citation: Eur Heart J. 2008 Dec;29(23):2877-85
references.pmid: 18826988
references.citation: Circulation. 2003 Jun 17;107(23):2908-13
references.pmid: 12796140
references.citation: Circulation. 2009 Jan 20;119(2):237-42
references.pmid: 19118249
references.citation: Eur Heart J. 2008 Apr;29(8):992-1000
references.pmid: 18263931
references.citation: Eur Heart J. 2008 Sep;29(17):2186-7; author reply 2187
references.pmid: 18617479
references.citation: Thromb Haemost. 2006 May;95(5):910-1
references.pmid: 16676093
references.citation: Am Heart J. 2009 Mar;157(3):562.e1-9
references.pmid: 19249429
references.citation: J Thromb Haemost. 2006 Nov;4(11):2516-8
references.pmid: 16938130
references.citation: JAMA. 2010 Feb 24;303(8):754-62
references.pmid: 20179285
references.citation: Ther Drug Monit. 2008 Jun;30(3):372-8
references.pmid: 18520610
references.citation: J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7
references.pmid: 17936152
references.citation: J Am Coll Cardiol. 2008 May 20;51(20):1925-34
references.pmid: 18482659
references.citation: J Thromb Haemost. 2009 May;7(5):897-9
references.pmid: 19220726
references.citation: J Thromb Haemost. 2006 Mar;4(3):542-9
references.pmid: 16371119
references.citation: Circulation. 2007 Feb 13;115(6):708-16
references.pmid: 17261652
references.citation: J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50
references.pmid: 17084243
references.citation: J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7
references.pmid: 17572245
references.citation: J Am Coll Cardiol. 2005 Nov 15;46(10):1820-6
references.pmid: 16286165
references.citation: Nat Rev Drug Discov. 2003 Jan;2(1):15-28
references.pmid: 12509756
references.citation: Am J Cardiol. 2009 Jul 1;104(1):46-51
references.pmid: 19576320
references.citation: Thromb Res. 2007;120(3):323-36
references.pmid: 17239428
references.citation: JAMA. 2002 Nov 20;288(19):2411-20
references.pmid: 12435254
references.citation: Circulation. 2009 Jun 30;119(25):3215-22
references.pmid: 19528337
references.citation: J Am Coll Cardiol. 2007 Nov 6;50(19):1822-34
references.pmid: 17980247
references.citation: Thromb Haemost. 2008 Feb;99(2):409-15
references.pmid: 18278193
references.citation: J Am Coll Cardiol. 2005 Nov 15;46(10):1827-32
references.pmid: 16286166
references.citation: J Am Coll Cardiol. 2008 Sep 30;52(14):1128-33
references.pmid: 18804738
references.citation: J Am Coll Cardiol. 2007 Feb 13;49(6):657-66
references.pmid: 17291930
references.citation: Lancet. 2001 Aug 18;358(9281):527-33
references.pmid: 11520521